Sutter Health to pay $13M for lab testing false claims
By 
Adrianne Appel2022-10-19T21:00:00
Sutter Health agreed to pay more than $13 million for violating the False Claims Act by billing the United States for toxicology tests it did not conduct but outsourced to other labs, the Department of Justice (DOJ) announced.
From August 2016 through June 2017, Sutter engaged in a laboratory services agreement with Navigant Network Alliance, in which Navigant sent urine specimens from physician offices and other laboratories nationwide to Sutter for testing. The DOJ alleged in its settlement agreement Sutter outsourced thousands of tests to third-party laboratories and still billed government health programs as if it had performed the tests at its own labs, a violation of the False Claims Act.
The DOJ alleged Sutter knowingly billed and was paid by the government programs for the tests it did not perform.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleCarter Healthcare, former execs to pay $30M in DOJ settlements over false claims
Home healthcare provider Carter Healthcare and its former chief executive officer and chief operations officer agreed to pay more than $30 million total under two settlements alleging the parties engaged in kickbacks to doctors and filed false claims.
-
ArticleDOJ intervenes in lawsuit against Cigna alleging Medicare fraud
Cigna created a home visit program for Medicare patients that artificially inflated government payments by intentionally incorrectly diagnosing tens of thousands of patients with serious illnesses, the Department of Justice charged in an intervenor complaint.
-
Article
DermaTran, other pharmacies settle with DOJ over pain cream false claims
DermaTran Health Solutions, its related pharmacy billing company, and three retail pharmacies agreed to pay more than $6.8 million to settle alleged violations of the False Claims Act for charging patients in federal health programs extra for pain relief creams.
More from Regulatory Enforcement
-
ArticleU.K. competition regulator ‘very likely’ to use new enforcement powers despite government’s pro-growth agenda
New powers granted to the U.K.’s main competition watchdog will result in greater scrutiny, tougher enforcement, and a stark warning for companies to review their sales and marketing promotions—especially since some practices have been pushed firmly into the spotlight thanks to legislation that came into effect last year.
-
ArticleSEC enforcement priorities revert back to basics
Recent pronouncements made by the U.S. Securities and Exchange Commission leadership, alongside the recent overhaul of the SEC Enforcement Manual, collectively signal a back-to-basics enforcement approach that appears beneficial for companies in their dealings with the agency.
-
ArticleFCA drive to reduce its investigation costs likely to add to compliance burden for smaller firms, warn experts
The U.K. financial regulator’s move towards “impactful deterrence” could see smaller and mid-size firms come increasingly under the spotlight as the watchdog aims to tackle market-wide concerns instead of primarily focusing on large players capable of doing the most harm.